$ORKA
Oruka Therapeutics, Inc.

2013 Q1 Form 10-Q Financial Statement

#000156459013000015 Filed on May 13, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $889.0K $980.0K
YoY Change -9.29% -35.1%
% of Gross Profit
Research & Development $180.0K $420.0K
YoY Change -57.14% -39.13%
% of Gross Profit
Depreciation & Amortization $10.00K $14.00K
YoY Change -28.57% -82.5%
% of Gross Profit
Operating Expenses $889.0K $1.410M
YoY Change -36.95% -35.91%
Operating Profit -$1.070M
YoY Change
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.071M -$1.407M
YoY Change -23.88% -36.33%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.071M -$1.407M
YoY Change -23.88% -36.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$53.50M -$70.50M
COMMON SHARES
Basic Shares Outstanding 3.038M 2.030M
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.500M $4.200M
YoY Change -16.67% -17.65%
Cash & Equivalents $3.537M $4.227M
Short-Term Investments
Other Short-Term Assets $500.0K $500.0K
YoY Change 0.0% 25.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.000M $4.700M
YoY Change -14.89% -14.55%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $100.0K
YoY Change -100.0% -83.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $200.0K
YoY Change -50.0% -33.33%
Total Long-Term Assets $100.0K $300.0K
YoY Change -66.67% -62.5%
TOTAL ASSETS
Total Short-Term Assets $4.000M $4.700M
Total Long-Term Assets $100.0K $300.0K
Total Assets $4.100M $5.000M
YoY Change -18.0% -20.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $100.0K
YoY Change 300.0% -85.71%
Accrued Expenses $400.0K $400.0K
YoY Change 0.0% -42.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $800.0K $600.0K
YoY Change 33.33% -60.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $800.0K $600.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $800.0K $600.0K
YoY Change 33.33% -64.71%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.300M $4.400M
YoY Change
Total Liabilities & Shareholders Equity $4.100M $5.000M
YoY Change -18.0% -20.63%

Cashflow Statement

Concept 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$1.071M -$1.407M
YoY Change -23.88% -36.33%
Depreciation, Depletion And Amortization $10.00K $14.00K
YoY Change -28.57% -82.5%
Cash From Operating Activities -$764.0K -$1.656M
YoY Change -53.86% -14.64%
INVESTING ACTIVITIES
Capital Expenditures $9.000K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$9.000K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.741M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.390M -60.00K
YoY Change -2416.67%
NET CHANGE
Cash From Operating Activities -764.0K -1.656M
Cash From Investing Activities -9.000K 0.000
Cash From Financing Activities 1.390M -60.00K
Net Change In Cash 617.0K -1.716M
YoY Change -135.96% -11.55%
FREE CASH FLOW
Cash From Operating Activities -$764.0K -$1.656M
Capital Expenditures $9.000K $0.00
Free Cash Flow -$773.0K -$1.656M
YoY Change -53.32% -14.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2004 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7000
CY2013Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
889000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5470000
us-gaap Restructuring Charges
RestructuringCharges
2413000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
6000000
abio Gain Loss On Assignment Of Patent Rights
GainLossOnAssignmentOfPatentRights
2000000
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
25282000
CY2013Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1000
CY2012Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1071000
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1407000
CY2007 us-gaap Net Income Loss
NetIncomeLoss
-13994000
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
-19689000
us-gaap Net Income Loss
NetIncomeLoss
-116000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-1071000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-1407000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3034763
CY2005 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000
CY2007 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
50000
us-gaap Net Income Loss
NetIncomeLoss
-69065000
CY2004 us-gaap Net Income Loss
NetIncomeLoss
-511000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-71346000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1790000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2281000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
245000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
781000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1071000
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1407000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70091000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2027716
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000
CY2003Q4 us-gaap Stockholders Equity
StockholdersEquity
-115000
CY2004Q4 us-gaap Stockholders Equity
StockholdersEquity
-619000
CY2006 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2006 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
-17000
CY2006 us-gaap Net Income Loss
NetIncomeLoss
-5241000
CY2006Q4 us-gaap Stockholders Equity
StockholdersEquity
-5744000
CY2007 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2008 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
545000
CY2008 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
399000
CY2008 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54000
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-19431000
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
-38178000
CY2009 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
781000
CY2009 abio Adjustment To Additional Paid In Capital Restricted Stock Release From Restriction
AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction
75000
CY2009 abio Adjustment To Additional Paid In Capital Conversion Of Warrants For Preferred Stock
AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock
36000
CY2009 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
11913000
CY2009 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
845000
CY2009 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
114000
CY2009 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
2000
CY2009 abio Adjustment To Additional Paid In Capital Estimated Fair Value Of Warrants Issued
AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued
377000
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-9138000
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
7412000
CY2010 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
458000
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-8420000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
6771000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
308000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-5364000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
5732000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
306000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-4320000
CY2013Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1421000
CY2013Q1 abio Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
12000
CY2013Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42000
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
10000
CY2012Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14000
us-gaap Paid In Kind Interest
PaidInKindInterest
211000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
42000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
91000
us-gaap Share Based Compensation
ShareBasedCompensation
2630000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
377000
us-gaap Accretion Expense
AccretionExpense
152000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
125000
abio Write Off Of Deferred Tax Liability
WriteOffOfDeferredTaxLiability
2281000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
263000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-83000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-267000
CY2013Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
157000
CY2012Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
72000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2663000
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-20000
CY2012Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-20000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-7346000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
312000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-134000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1813000
CY2013Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
88000
CY2012Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-160000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-19133000
CY2013Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-8000
CY2012Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-8000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
8000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-764000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1656000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-98185000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
30392000
us-gaap Other Payments To Acquire Businesses
OtherPaymentsToAcquireBusinesses
1186000
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1888000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15369000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
358000
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
2000000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45045000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
10841000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
4000000
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
38000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
32316000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1741000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15850000
CY2012Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
60000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
60000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4000000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
105000
CY2013Q1 abio Repayment Of Principal On Vendor Finance Agreement
RepaymentOfPrincipalOnVendorFinanceAgreement
43000
abio Repayment Of Principal On Vendor Finance Agreement
RepaymentOfPrincipalOnVendorFinanceAgreement
323000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1390000
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-60000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56677000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
617000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1716000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3537000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5943000
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4227000
CY2013Q1 us-gaap Interest Paid
InterestPaid
1000
us-gaap Interest Paid
InterestPaid
116000
abio Accrued Interest On Notes Payable Converted To Equity
AccruedInterestOnNotesPayableConvertedToEquity
163000
abio Warrant Issued In Connection With Credit Facility
WarrantIssuedInConnectionWithCreditFacility
111000
abio Accrued Deferred Transaction Costs
AccruedDeferredTransactionCosts
482000
CY2013Q1 abio Vendor Finance Agreement
VendorFinanceAgreement
131000
CY2012Q1 abio Vendor Finance Agreement
VendorFinanceAgreement
134000
abio Vendor Finance Agreement
VendorFinanceAgreement
131000
CY2013Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Concentrations of Credit Risk </font></p> <p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p> <p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, money market fund accounts and debt securities with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </font></p> </div>
abio Depreciation And Amortization Expense Since Inception
DepreciationAndAmortizationExpenseSinceInception
1800000
CY2013Q1 abio Anticipated Period To Start Atrial Fibrillation Trial
AnticipatedPeriodToStartAtrialFibrillationTrial
P6M
CY2013Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 6 reverse split
CY2013Q1 abio Revenue Generated
RevenueGenerated
0
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3037546
CY2012Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2030499
CY2013Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
-2783
CY2012Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
-2783
CY2013Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
3034763
CY2012Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
2027716
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1300000
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
604000
CY2009Q1 us-gaap Business Acquisition Cost Of Acquired Entity Purchase Price
BusinessAcquisitionCostOfAcquiredEntityPurchasePrice
11900000
CY2009Q1 us-gaap Business Acquisition Purchase Price Allocation Assets Acquired Liabilities Assumed Net
BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet
37200000
CY2009Q1 us-gaap Business Acquisition Purchase Price Allocation Current Assets Cash And Cash Equivalents
BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents
45500000
CY2009Q1 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
25300000
CY2013Q1 abio Cash Equivalents Consisting Of Money Market Funds With Maturities
CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities
P90D
CY2013Q1 abio Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0
CY2013Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
508000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
533000
CY2013Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
486000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
510000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10000
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2008Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
15000
CY2011Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
4500
CY2013Q1 abio Lease Term
LeaseTerm
P5Y
CY2013Q1 abio Extended Lease Term
ExtendedLeaseTerm
P3Y
CY2013Q1 abio Rights To Extend Term
RightsToExtendTerm
Two additional three year periods
CY2013Q1 abio Allow To Terminate Agreement
AllowToTerminateAgreement
P3M
CY2013Q1 abio One Time Payment To Landlord For New Leased Premises
OneTimePaymentToLandlordForNewLeasedPremises
200000
CY2013Q1 us-gaap Tenant Reimbursements
TenantReimbursements
593000
CY2013Q1 us-gaap Deferred Rent Credit
DeferredRentCredit
8000
CY2013Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
12000
CY2012Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
12000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
527000
CY2013Q1 abio Lease Month Expiration Date
LeaseMonthExpirationDate
2013-06
CY2013Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
20000
CY2008Q3 abio Milestone Payment Made By Company
MilestonePaymentMadeByCompany
500000
CY2008Q3 abio Expected Milestone Payments Upon Approval
ExpectedMilestonePaymentsUponApproval
8000000
CY2008Q3 abio Another Expected Milestone Payments Upon Approval
AnotherExpectedMilestonePaymentsUponApproval
5000000
CY2008Q3 abio Minimum Percentage Of Royalty Obligation
MinimumPercentageOfRoyaltyObligation
0.125
CY2008Q3 abio Maximum Percentage Of Royalty Obligation
MaximumPercentageOfRoyaltyObligation
0.25
CY2008Q3 abio Percentage Of Royalty Obligated To Pay Under Its Original License Agreement
PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement
0.05
CY2008Q3 abio Minimum Percentage Of Range Of Royalties That Can Be Buy Down
MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown
0.125
CY2008Q3 abio Maximum Percentage Of Range Of Royalties That Can Be Buy Down
MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown
0.17
CY2008Q3 abio Milestone Payment Due Period
MilestonePaymentDuePeriod
P6M
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42000
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2630000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
144019
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
6259
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
137760
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
123408
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
136208
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.28
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
16.53
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.36
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.82
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.39
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M28D
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M21D
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M13D
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y10M17D
CY2013Q1 us-gaap Income Tax Examination Liability Recorded
IncomeTaxExaminationLiabilityRecorded
0

Files In Submission

Name View Source Status
0001564590-13-000015-index-headers.html Edgar Link pending
0001564590-13-000015-index.html Edgar Link pending
0001564590-13-000015.txt Edgar Link pending
0001564590-13-000015-xbrl.zip Edgar Link pending
abio-10q_20130331.htm Edgar Link pending
abio-20130331.xml Edgar Link completed
abio-20130331.xsd Edgar Link pending
abio-20130331_cal.xml Edgar Link unprocessable
abio-20130331_def.xml Edgar Link unprocessable
abio-20130331_lab.xml Edgar Link unprocessable
abio-20130331_pre.xml Edgar Link unprocessable
abio-ex31_2013033039.htm Edgar Link pending
abio-ex31_2013033040.htm Edgar Link pending
abio-ex32_2013033041.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending